FRAGMIN Resource Center
Eisai offers resources to assist you and your staff in the education and administration of FRAGMIN.Learn more >
FRAGMIN Self-Injection Demo Video
This Self-Injection Demo Video walks patients through the steps of injecting with a fixed-dose or graduated syringe.Learn more >
FRAGMIN Patient Education and Administration Kits
Educational materials, including an easy-to-understand reference chart, a step-by-step product brochure, and a how-to demonstration video, introduce patients to the use of FRAGMIN at home.Learn more >
Incidence of major bleeding and thrombocytopenia comparable
Bleeding was assessed at day 21 and classified as major if it was intraocular, spinal/epidural, intracranial, or retroperitoneal; if hemoglobin decreased ≥2 g/dL; if it required transfusion of ≥2 units of blood; if it required significant medical or surgical intervention; or if it resulted in death. All other bleeding was classified as minor.
†Major bleeding by day 14 was 0.4% (8/1848) for FRAGMIN vs 0% (0/1833) for placebo.